Following the issuance of the “Registration Certificate for Pharmaceutical Packaging Materials and Containers” by the National Medical Products Administration on May 10, 2016, Beijing Huonland Pharmaceutical Co., Ltd. received another approval—“Clinical Trial Approval for Moxifloxacin Hydrochloride Eye Drops”—on May 18, 2016, with approval number 2016L05297. This represents a significant milestone in Huonland’s R&D efforts in the field of new ophthalmic drugs. The company will carefully prepare the clinical trial protocol and strive to complete the trials at an early date.

Since the completion of the Huonland Ophthalmic Pharmaceutical Production Base in 2014, the company has been actively preparing for GMP certification and conducting research and development on a series of ophthalmic drugs. Currently, the company has three generic drug candidates in the stage of application for production approval, and one new drug candidate is about to enter clinical trials, thus establishing a well-organized product pipeline. With the goal of building Asia’s largest ophthalmic pharmaceutical production base, the company will adopt scientific and standardized management practices to produce high-quality medications, bringing hope and relief to patients suffering from eye diseases.